Comparison of alternate day atorvastatin treatment to daily treatment in maintaining LDL-Cholesterol targets in patients with variable coronary risk profile
Journal of Cardiovascular Pharmacology, 03/29/2012Pattanaika S et al.
Alternate–day treatment of atorvastatin was inferior to daily treatment in maintaining the INCEP–ATPII goal.
This randomized, open label trial included 300 patients of dyslipidemia or coronary artery disease on stable doses of atorvastatin.
These patients met their respective NCEP–ATPIII cholesterol goals and randomized to receive the same doses of atorvastatin every day (QD) or every–other–day (QOD) in 1:1 ratio for 12 weeks.
The efficacy criteria were (1)proportion of patients maintaining the LDL–C goal (2)comparison of changes in the TC, LDL–C, HDL–C and TG levels from baseline.
Proportions of patients maintaining their LDL–C goals in QD and QOD groups at 6 weeks were 83.9%(60.3–97.5) Vs 70.9%(59.3–82.5) [p< 0.01] and at 12weeks were 84.6%(70.9–98.3) Vs 73.8%(63.8–83.8) [p< 0.05].
Per–protocol analysis showed 95.5%(80.0–111.0) Vs 79.1%(66.2–92.0)[p< 0.001] patients at 6 weeks and 91.9%(82.0–106.8) Vs 77.4%(64.8–90) [p< 0.05] patients at 12 weeks had maintained their LDL–C goals in QD and QOD groups.
Significant increase was observed in the levels of TC, LDL–C and TG at 6 and 12 weeks compared to baseline values in the QOD group.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.